Stifel Nicolaus initiates its coverage on Supernus Pharmaceuticals SUPN with a Buy rating and a price target of $15 per share.
Stifel Nicolaus comments, "With extensive experience in product development, first as a
subsidiary of Shire and then independently, the company is developing a broad central nervous system (CNS) portfolio with proprietary extended-release technologies that have been validated through numerous marketed drugs. Supernus has two near-term opportunities in epilepsy, SPN-538 and SPN-804, approaching FDA decision in the coming months, as well as a balanced pipeline of other CNS drugs for attention deficit hyperactivity disorder (ADHD) and depression, with a view to providing enhanced therapeutic benefits for specific unmet needs in each indication."
SUPN closed at $5.94 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in